MF研究者総覧

教員活動データベース

Expression of SATB2, RUNX2, and SOX9 and possible osteoblastic and chondroblastic differentiation in chondroblastoma

発表形態:
原著論文
主要業績:
主要業績
単著・共著:
共著
発表年月:
2023年01月
DOI:
10.1016/j.prp.2022.154239
会議属性:
指定なし
査読:
有り
リンク情報:

日本語フィールド

著者:
*Toda Y, Yamamoto H, Iwasaki T, Ishihara S, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, Kiyozawa D, Yamada Y, Kohashi K, Kimura A, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y
題名:
Expression of SATB2, RUNX2, and SOX9 and possible osteoblastic and chondroblastic differentiation in chondroblastoma
発表情報:
Pathol Res Pract 巻: 241 ページ: 154239
キーワード:
Chondroblastoma; Immunohistochemistry; Osteoblastic precursor; RUNX2; SATB2
概要:
Chondroblastoma (CB) is histologically characterized by oval to polygonal-shaped mononuclear neoplastic cells, multinucleated osteoclastic giant cells, and eosinophilic matrix with occasional calcification. Genetically, the majority of CBs harbor H3F3B p.K36M mutation. Despite the historical nomenclature, it has been reported that the matrix of CB is similar to osteoid rather than true cartilage; however, it remains unclear whether neoplastic cells in CB have the potential for osteoblastic differentiation. To clarify this issue, we immunohistochemically examined the expression of osteogenic and chondrogenic markers (SATB2, RUNX2, p63, and SOX9) as well as H3K36M mutant protein in 33 cases of CB. All 33 cases of CB were positive for H3K36M, while SATB2, RUNX2, p63, and SOX9 were expressed in 30/33 (91%), 33/33 (100%), 29/33 (88%), and 31/32 (97%) CB cases, respectively. Our immunohistochemical results suggest that neoplastic cells in CB frequently express both osteogenic and chondrogenic markers and may have an intermediate feature of osteoblastic and chondroblastic nature.
抄録:

英語フィールド

Author:
*Toda Y, Yamamoto H, Iwasaki T, Ishihara S, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, Kiyozawa D, Yamada Y, Kohashi K, Kimura A, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Mawatari M, Oda Y
Title:
Expression of SATB2, RUNX2, and SOX9 and possible osteoblastic and chondroblastic differentiation in chondroblastoma
Announcement information:
Pathol Res Pract Vol: 241 Page: 154239
Keyword:
Chondroblastoma; Immunohistochemistry; Osteoblastic precursor; RUNX2; SATB2
An abstract:
Chondroblastoma (CB) is histologically characterized by oval to polygonal-shaped mononuclear neoplastic cells, multinucleated osteoclastic giant cells, and eosinophilic matrix with occasional calcification. Genetically, the majority of CBs harbor H3F3B p.K36M mutation. Despite the historical nomenclature, it has been reported that the matrix of CB is similar to osteoid rather than true cartilage; however, it remains unclear whether neoplastic cells in CB have the potential for osteoblastic differentiation. To clarify this issue, we immunohistochemically examined the expression of osteogenic and chondrogenic markers (SATB2, RUNX2, p63, and SOX9) as well as H3K36M mutant protein in 33 cases of CB. All 33 cases of CB were positive for H3K36M, while SATB2, RUNX2, p63, and SOX9 were expressed in 30/33 (91%), 33/33 (100%), 29/33 (88%), and 31/32 (97%) CB cases, respectively. Our immunohistochemical results suggest that neoplastic cells in CB frequently express both osteogenic and chondrogenic markers and may have an intermediate feature of osteoblastic and chondroblastic nature.


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.